Celldex (CLDX) AI Stock Analysis

• Market Cap: $1.78B
• Dividend Yield: N/A
• Average Volume (3M): 849.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: -73.94%
• EPS Growth: -31.70%
• Country: US
• Employees: 186
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.01
• Shares Outstanding: 66,449,470
• 10 Day Avg. Volume: 774,204
• 30 Day Avg. Volume: 849,122
• PEG Ratio: 0.64
• Price to Book (P/B): 2.18
• Price to Sales (P/S): 231.80
• P/FCF Ratio: -10.19
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 439.88
• Enterprise Value/Gross Profit: 642.16
• Enterprise Value/Ebitda: -4.64
• 1Y Price Target: $54.67
• Price Target Upside: 104.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -3.66
• Revenue Forecast (FY): $2.79M

• Rating: 41 Neutral
• Price Target: $24.50 ▼(-8.55% Downside)

Celldex's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis shows a lack of strong momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall score.

Positive Factors

Innovative Pipeline

Celldex's innovative pipeline, including Barzolvolimab, showcases strong potential in immuno-oncology, enhancing its competitive edge in the biotech sector.

Leadership in Mast Cell Biology

Leadership in mast cell biology positions Celldex as a frontrunner in developing targeted therapies, potentially leading to breakthrough treatments and market differentiation.

Strategic Leadership Appointment

The appointment of an experienced CCO strengthens Celldex's commercial strategy, potentially improving market penetration and revenue generation.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in product commercialization and market demand, which could hinder long-term financial stability and growth.

Persistent Losses

Persistent losses reflect operational inefficiencies and high R&D costs, posing risks to sustainability and necessitating strategic adjustments for profitability.

Weak Cash Flow

Weak cash flow limits Celldex's ability to fund operations and invest in R&D, potentially impacting its capacity to innovate and compete effectively.

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

How the Company Makes Money

Celldex Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company has a revenue model that includes proceeds from collaborations and partnerships with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of approved products. Additionally, Celldex may engage in licensing agreements for its technology platforms or products, providing another stream of income. The success of its clinical trials and the subsequent approval of its therapies are critical to its earnings potential, as market demand for effective cancer treatments can significantly impact revenue. Furthermore, government grants and funding for research and development can also contribute to the company's financial resources.

Celldex Financial Statement Overview

Summary

Celldex faces significant financial challenges, characterized by declining revenues, persistent losses, and weak cash flow generation. Despite a strong equity position, profitability metrics are concerning with negative net profit and EBIT margins. The biotechnology industry often involves high R&D costs, contributing to these financial pressures.

Income Statement

Celldex's income statement reflects significant challenges. The company has experienced a declining revenue trend, with a negative revenue growth rate of -23.39% in the TTM period. Profitability metrics are concerning, with a negative net profit margin of -34.47% and EBIT margin of -40.54%, indicating substantial operational losses. Despite a high gross profit margin of 85.86%, the overall financial health is weakened by persistent net losses.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.0046, suggesting minimal leverage risk. However, the return on equity is negative at -27.62%, indicating that the company is not generating profits from its equity base. The equity ratio is relatively stable, but the negative ROE highlights profitability challenges.

Cash Flow

Cash flow analysis reveals a negative operating cash flow, with an operating cash flow to net income ratio of -5.65, indicating cash flow challenges. Although free cash flow has shown slight growth, the overall cash flow position remains weak, with a free cash flow to net income ratio of 1.00, suggesting limited cash generation relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.60M	7.02M	6.88M	2.36M	4.65M	7.42M
Gross Profit	1.78M	-156.53M	-111.13M	-79.90M	-48.66M	-35.12M
EBITDA	-246.28M	-191.90M	-139.03M	-104.20M	-66.08M	-45.64M
Net Income	-224.53M	-157.86M	-141.43M	-112.33M	-70.51M	-59.78M
Balance Sheet
Total Assets	648.44M	792.34M	465.63M	352.74M	444.65M	235.84M
Cash, Cash Equivalents and Short-Term Investments	583.22M	725.28M	421.70M	304.95M	408.25M	194.42M
Total Debt	2.62M	3.81M	2.54M	4.03M	3.04M	3.48M
Total Liabilities	50.08M	45.34M	36.46M	26.53M	25.18M	26.48M
Stockholders Equity	598.36M	747.00M	429.17M	326.20M	419.48M	209.36M
Cash Flow
Free Cash Flow	-181.67M	-159.70M	-109.11M	-105.56M	-62.16M	-41.96M
Operating Cash Flow	-179.48M	-157.78M	-107.29M	-103.73M	-60.91M	-40.40M
Investing Cash Flow	177.69M	-290.13M	-105.78M	89.94M	-216.16M	-98.22M
Financing Cash Flow	1.43M	441.45M	218.46M	4.08M	272.37M	171.23M

Celldex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 26.79 is above the 20-day moving average (MA) of 24.94, above the 50-day MA of 25.78, and above the 200-day MA of 22.18, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 58.75 is Neutral, neither overbought nor oversold. The STOCH value of 94.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.

Celldex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	59 Neutral	$2.10B	-5.29	-47.40%	―	23340.07%	18.06%
JANX	56 Neutral	$2.09B	―	-12.48%	―	-23.37%	-42.45%
TVTX	55 Neutral	$3.22B	―	-410.78%	―	114.22%	77.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ETNB	42 Neutral	―	―	-86.86%	―	―	-82.75%
CLDX	41 Neutral	$1.78B	―	-32.44%	―	-73.94%	-31.70%
VERA	39 Underperform	$1.54B	-6.32	-73.25%	―	―	-53.44%

Celldex Corporate Events

Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress

Celldex Therapeutics is a biotechnology company focused on developing antibody-based treatments for allergic, inflammatory, and autoimmune disorders. In its third-quarter 2025 earnings report, Celldex highlighted significant progress in its clinical pipeline, including positive Phase 2 results for barzolvolimab in treating chronic spontaneous urticaria and cold urticaria, as well as promising data for CDX-622, a bispecific antibody. The company reported a net loss of $67 million for the quarter, primarily due to increased research and development expenses, which rose to $62.9 million. Despite a decrease in revenue compared to the previous year, Celldex maintains a strong cash position of $583.2 million, which is expected to support operations through 2027. Looking ahead, Celldex plans to continue advancing its pipeline with multiple data readouts expected in 2026, while preparing for the potential commercialization of barzolvolimab.

Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study

Study Overview: Celldex Therapeutics is conducting a Phase 2 clinical trial titled ‘A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis.’ The study aims to evaluate the effectiveness and safety of barzolvolimab in treating prurigo nodularis, a chronic skin condition characterized by itchy nodules. This research is significant as it could lead to a new treatment option for patients suffering from this debilitating condition.

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria

Study Overview: Celldex Therapeutics is conducting a Phase 3 study titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)’. The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to current antihistamine treatments.

Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment

Celldex Therapeutics is conducting a Phase 3 clinical trial titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)’. The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to standard H1-antihistamine treatments.

Celldex Halts Barzolvolimab Development for EoE

On August 19, 2025, Celldex Therapeutics announced results from its Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). The study met its primary endpoint by demonstrating significant mast cell depletion in the gastrointestinal tract. However, this did not translate into improved clinical outcomes, leading Celldex to halt further development of barzolvolimab for EoE. The company remains committed to advancing barzolvolimab in other conditions where mast cells play a crucial role, such as chronic urticaria and atopic dermatitis.

The most recent analyst rating on (CLDX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.

Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. In its latest earnings report for the quarter ending June 30, 2025, Celldex reported a significant increase in research and development expenses, reflecting its ongoing commitment to advancing its drug candidates, particularly barzolvolimab, across multiple mast cell-driven diseases. The company’s total revenues decreased compared to the previous year, primarily due to reduced contract and grant income, while operating losses widened as a result of increased investment in research and development. Despite the financial losses, Celldex maintains a strong cash position, with $630.3 million in cash, cash equivalents, and marketable securities, ensuring its ability to fund operations for at least the next twelve months. Looking forward, Celldex aims to continue its focus on advancing its clinical programs and exploring strategic partnerships to support its long-term growth and development goals.